ClinicalTrials.gg
CompletedNCT01618968Updated May 19, 2014Results posted

Comparison of Methotrexate (MTX) and the VIBEX™ MTX Device

A Phase 2 interventional study of MTX in Rheumatoid Arthritis (RA), sponsored by Antares Pharma Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-05-19.

Sponsored by Antares Pharma Inc. (part of Halozyme Therapeutics) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
49
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 113 studies testing methotrexate in Arthritis, Rheumatoid — 8 open to participants now, 10 under way, 2 of them phase 3. Methotrexate · Arthritis, Rheumatoid.

Enrollment
85th of 113
49 · median 130
Started
2012
with 10 others
Phase 2
10 of 113
2 open now
Registered
62nd of 113
by date

Among the 113 studies testing methotrexate in Arthritis, Rheumatoid, this one is the 85th largest by enrollment, is one of 11 that started in 2012, is one of 10 in phase 2, and was the 62nd registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

8 of the 113 studies testing methotrexate in Arthritis, Rheumatoid are open now, in 5 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About methotrexate

Methotrexate: first FDA approval 1953 (METHOTREXATE SODIUM), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 113 studies testing methotrexate in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

Relative Bioavailability Comparison study

Read the detailed description

A Phase 2, Open-Label, Randomized, 3-Way Crossover Study to Compare the Relative Bioavailability of Oral Methotrexate and the VIBEX™ MTX Device in Adult Subjects With Rheumatoid Arthritis

03

Conditions studied

  • Rheumatoid Arthritis (RA)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patients ≥18 years of age, diagnosed with Rheumatoid Arthritis

Exclusion criteria

Exclusion Criteria:

  • Pregnant females
  • Any other disease or disorder which, in the opinion of the investigator might put the subject at risk
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
49 participants (actual)

Study arms

  • Experimental
    10 mg Methotrexate (MTX)

    MTX dose group was assigned based on the subject's current therapeutic regimen of MTX and rheumatoid arthritis disease status. The sequence of treatments A, B and C was randomly assigned.

    Drug: MTX

  • Experimental
    15 mg MTX

    MTX dose group was assigned based on the subject's current therapeutic regimen of MTX and rheumatoid arthritis disease status. The sequence of treatments A, B and C was randomly assigned.

    Drug: MTX

  • Experimental
    20 mg MTX

    MTX dose group was assigned based on the subject's current therapeutic regimen of MTX and rheumatoid arthritis disease status. The sequence of treatments A, B and C was randomly assigned.

    Drug: MTX

  • Experimental
    25 mg MTX

    MTX dose group was assigned based on the subject's current therapeutic regimen of MTX and rheumatoid arthritis disease status. The sequence of treatments A, B and C was randomly assigned.

    Drug: MTX

Interventions

  • DrugMTX

    * Treatment A - 1 dose (4, 6, 8 or 10 tablets respectively to make up 10 mg, 15 mg, 20 mg or 25 mg MTX - per subject's dose group) * Treatment B - SC injection using VIBEX MTX device into abdomen (VIBEX MTX device pre-filled with 10 mg, 15 mg, 20 mg or 25 mg MTX) * Treatment C - SC injection using VIBEX MTX device into thigh (VIBEX MTX device pre-filled with 10 mg, 15 mg, 20 mg or 25 mg MTX)

    Also known as: Commercially available 2.5 mg MTX oral tablets, VIBEX MTX

06

What researchers measure

Primary outcomes

  1. Dose-Normalized AUC[0-Inf] for MTX

    Dose-normalized area under the curve from time zero to infinity (AUC\[0-inf\]/Dose) for each treatment

    Time frame: 24 Hour period

  2. Dose-Normalized AUC[0-24] for MTX

    Dose-normalized area under the curve from time zero to 24 hours (AUC\[0-24\]/Dose) for each treatment

    Time frame: 24 Hour period

  3. Dose-Normalized Cmax for MTX

    Dose-normalized maximum observed concentration (Cmax) for each treatment

    Time frame: 24 Hour period

07

Results

Posted May 8, 2014

Participant flow

Subjects were screened and enrolled at 4 sites in the US. Approximately equal number of subjects on 10 mg, 15 mg, 20 mg and 25 mg doses were recruited. The dose group was determined by the Investigator based on subject's current therapeutic regimen of MTX and disease status. The subject's dose was the same for the entire study

Participant flow — Overall Study
Milestone10mg MTX15mg MTX20mg MTX25mg MTX
Started13121212
Received treatment a12121211
Received treatment b13121212
Received treatment c12121211
Completed12121211
Not completed1001
Withdrew: Adverse event1000
Withdrew: Death0001

Outcome measures

PrimaryDose-Normalized AUC[0-Inf] for MTX

Dose-normalized area under the curve from time zero to infinity (AUC\[0-inf\]/Dose) for each treatment

Time frame:
24 Hour period
Reported as:
Mean · ng*hr/mL/mg
Dose-Normalized AUC[0-Inf] for MTX
ng*hr/mL/mgTreatment ATreatment BTreatment C
Dose-Normalized AUC[0-Inf] for MTX109.47 ± 39.19140.84 ± 46.66136.45 ± 46.675
Statistical analysis
  • Treatment A vs Treatment B · Test / reference ratio: 127.99 · 90% CI 121.61 to 134.70
  • Treatment A vs Treatment C · Test / reference ratio: 125.48 · 90% CI 119.43 to 131.84
  • Treatment B vs Treatment C · Test / reference ratio: 101.85 · 90% CI 99.41 to 104.36
PrimaryDose-Normalized AUC[0-24] for MTX

Dose-normalized area under the curve from time zero to 24 hours (AUC\[0-24\]/Dose) for each treatment

Time frame:
24 Hour period
Reported as:
Mean · ng*hr/mL/mg
Dose-Normalized AUC[0-24] for MTX
ng*hr/mL/mgTreatment ATreatment BTreatment C
Dose-Normalized AUC[0-24] for MTX107.64 ± 37.732137.88 ± 44.513133.78 ± 44.406
Statistical analysis
  • Treatment A vs Treatment B · Test / reference ratio: 127.65 · 90% CI 121.28 to 134.36
  • Treatment A vs Treatment C · Test / reference ratio: 125.20 · 90% CI 119.16 to 131.55
  • Treatment B vs Treatment C · Test / reference ratio: 101.82 · 90% CI 99.39 to 104.31
PrimaryDose-Normalized Cmax for MTX

Dose-normalized maximum observed concentration (Cmax) for each treatment

Time frame:
24 Hour period
Reported as:
Mean · ng/mL/mg
Dose-Normalized Cmax for MTX
ng/mL/mgTreatment ATreatment BTreatment C
Dose-Normalized Cmax for MTX22.697 ± 7.49621.935 ± 8.24318.436 ± 5.321
Statistical analysis
  • Treatment A vs Treatment B · Test / reference ratio: 94.83 · 90% CI 86.42 to 104.06
  • Treatment A vs Treatment C · Test / reference ratio: 82.12 · 90% CI 76.16 to 88.55
  • Treatment B vs Treatment C · Test / reference ratio: 115.63 · 90% CI 108.83 to 122.86

Adverse events

Collected over The Safety Population was defined as all randomized subjects who received at least 1 dose of study drug. The Safety Population included 49 subjects.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
10mg MTX—0/13 (0%)2/13 (15.4%)
15mg MTX—1/12 (8.3%)0/12 (0%)
20mg MTX—0/12 (0%)1/12 (8.3%)
25mg MTX—1/12 (8.3%)0/12 (0%)
Most frequent serious events
Most frequent serious events
Event10mg MTX15mg MTX20mg MTX25mg MTX
Sick Sinus Syndrome (15 mg Vibex MTX SC Thigh)Cardiac disorders0/131/120/120/12
Myocardial Infarction (25 mg Vibex MTX SC Abdomen)Cardiac disorders0/130/120/121/12
Most frequent other events
Most frequent other events
Event10mg MTX15mg MTX20mg MTX25mg MTX
Nausea (20 mg MTX Oral)Gastrointestinal disorders0/130/121/120/12
Fatigue (10 mg Vibex MTX SC Thigh)General disorders1/130/120/120/12
Rheumatoid Arthritis (10 mg Vibex MTX SC Abdomen)Musculoskeletal and connective tissue disorders1/130/120/120/12

Baseline characteristics

In total, 50 subjects were randomized, of which 49 were included in the safety population. Of 49, 47 completed the study and 2 discontinued from the study after first dose.

Age, Continuous
Age, Continuous(years)10mg MTX15mg MTX20mg MTX25mg MTXTotal
Mean62.9 ± 12.5163.4 ± 7.4960.0 ± 10.4059.0 ± 11.5361.4 ± 10.53
Sex: Female, Male
Sex: Female, Male(Participants)10mg MTX15mg MTX20mg MTX25mg MTXTotal
Female1158731
Male274518
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)10mg MTX15mg MTX20mg MTX25mg MTXTotal
White1211101144
African American11215
Region of Enrollment
Region of Enrollment(participants)10mg MTX15mg MTX20mg MTX25mg MTXTotal
United States1312121249
08

Study locations

1 site
  • Altoona Center for Clinical Research
    Duncansville, Pennsylvania 16635, United States
09

References and documents

Publications

  • Schiff MH, Jaffe JS, Freundlich B. Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses >/=15 mg may be overcome with subcutaneous administration. Ann Rheum Dis. 2014 Aug;73(8):1549-51. doi: 10.1136/annrheumdis-2014-205228. Epub 2014 Apr 12. PubMed 24728329 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2012, a primary completion of Aug 2012 and a completion of Aug 2012. It does not say whether these dates are actual or estimated.

Results were first posted in May 2014, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2012
First posted
Jun 14, 2012
Start
May 2012
Primary completionActual
Aug 2012
CompletionActual
Aug 2012
Results first posted
May 8, 2014
Last update
May 19, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 19, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01618968
Responsible party
Sponsor
First posted
Jun 14, 2012
Start date
May 2012
Primary completion
Aug 2012
Completion
Aug 2012
Results posted
May 8, 2014
Last update
May 19, 2014

Study contacts

Alan J Kivitz, MD;CPI
principal investigator · Altoona Center for Clinical Research

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Methotrexate

Start the discussion